Emerging Insights and Perspectives From COMMANDS (Luspatercept in LR-MDS)

Opinion
Video

Panelists discuss key takeaways from the COMMANDS trial, including the analysis of biomarkers in responders by ribosomal stress status (Hayati et al, EHA 2024), the impact of luspatercept on cell lineages (Garcia-Manero et al, EHA 2024), and the long-term clinical value of extended RBC transfusion independence (RBC-TI) (Garcia-Manero et al, ASH 2024).

  1. Please briefly discuss these additional key takeaways from COMMANDS:
    1. Analysis of biomarkers in responders by ribosomal stress status: Hayati et al, EHA 2024.
    2. Impact of luspatercept on cell lineages: Garcia-Manero et al, EHA 2024.
    3. Long term clinical value, extended RBC-TI: Garcia-Manero et al, ASH 2024

Recent Videos
Hope S. Rugo, MD, FASCO, is featured in this series.
Hope S. Rugo, MD, FASCO, is featured in this series.
1 KOL is featured in this series.
1 expert in this video